JeanMDostouMD
Endocrinology • Chapel Hill, NCDiabetes, Lipid Metabolism
Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine
Dr. Dostou is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Meadowmont Village Cir
Chapel Hill, NC 27517Phone+1 984-974-2950Fax+1 984-974-2924- Is this information wrong?
Education & Training
University of RochesterFellowship, Endocrinology, Diabetes, and Metabolism, 1995 - 1998- University of RochesterResidency, Internal Medicine, 1992 - 1995
The Warren Alpert Medical School of Brown UniversityClass of 1992
Certifications & Licensure
NC State Medical License 1998 - 2025
NY State Medical License 1994 - 2000- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Fellow (FACE) American Association of Clinical Endocrinology
Publications & Presentations
PubMed
- 66 citationsAnti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-c...Matthias von Herrath, Stephen C. Bain, Bruce W. Bode, Jesper Ole Clausen, Ken Coppieters, Leylya Gaysina, Janusz Gumprecht, Troels Krarup Hansen, Chantal Mathieu, Cris...> ;The Lancet. Diabetes & Endocrinology. 2021 Apr 1
- 188 citationsAlefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patientsMark R. Rigby, Kristina M. Harris, Ashley Pinckney, Linda A. DiMeglio, Marc Rendell, Eric I. Felner, Jean M. Dostou, Stephen E. Gitelman, Kurt J. Griffin, Eva Tsalikia...> ;The Journal of Clinical Investigation. 2015 Aug 3
- 130 citationsTargeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R. Rigby, Linda A. DiMeglio, Marc Rendell, Eric I. Felner, Jean M. Dostou, Stephen E. Gitelman, Chetanbabu M. Patel, Kurt J. Griffin, Eva Tsalikian, Peter A. Gott...> ;The Lancet. Diabetes & Endocrinology. 2013 Dec 1
- Join now to see all
Hospital Affiliations
University of North Carolina HospitalsChapel Hill, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
